BNT 002Alternative Names: BNT-002
Latest Information Update: 08 Jul 2016
At a glance
- Originator Boryung Pharmaceutical
- Class Antidementias
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase III Alzheimer's disease
Most Recent Events
- 06 May 2016 Phase-III clinical trials in Alzheimer's disease in South Korea (unspecified route)